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Aims Antihypertensive drugs are included in the medical therapy of vascular Ehlers–Danlos syndrome (vEDS). The
b-blocker celiprolol has been suggested to prevent arterial damage in vEDS, but the underlying mechanism remains
unclear. It is also unknown whether the widely used angiotensin II receptor type 1 antagonist losartan has a thera-
peutic effect in vEDS. Here, we evaluated the impact of celiprolol and losartan on the biomechanical integrity of
the vEDS thoracic aorta.
....................................................................................................................................................................................................
Methods
and results
We established a new approach to measure the maximum tensile force at rupture of uniaxially stretched murine
thoracic aortic rings. In a vEDS model, which we (re-)characterized here at molecular level, heterozygous mice
showed a significant reduction in the rupture force compared to wild-type mice, reflecting the increased mortality
due to aortic rupture. For the assessment of treatment effects, heterozygous mice at 4 weeks of age underwent a
4-week treatment with celiprolol, losartan, and, as a proof-of-concept drug, the matrix metalloproteinase inhibitor
doxycycline. Compared to age- and sex-matched untreated heterozygous mice, treatment with doxycycline or celi-
prolol resulted in a significant increase of rupture force, whereas no significant change was detected upon losartan
treatment.
....................................................................................................................................................................................................
Conclusions In a vEDS model, celiprolol or doxycycline, but not losartan, can improve the biomechanical integrity of the aortic
wall, thereby potentially reducing the risk of dissection and rupture. As doxycycline is a broad-spectrum antibiotic
with considerable side effects, celiprolol may be more suitable for a long-term therapy and thus rather indicated for
the medication of patients with vEDS.
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1. Introduction
Vascular Ehlers–Danlos syndrome (vEDS; OMIM #130050) is a rare
autosomal-dominant connective tissue disorder caused by heterozygous
mutations in the COL3A1 gene (OMIM *120180) with an estimated prev-
alence of 2 in 100 000 individuals.1 Typical vEDS is characterized by
thin, translucent skin, easy bruising, characteristic facial features, and fra-
gility of connective tissues, affecting hollow organ walls (e.g. uterus, intes-
tine) including medium- and large-sized arteries.2 Some COL3A1
mutations, however, may not cause typical clinical signs of vEDS other
than vascular events. The increased risk of arterial dissection or rupture
may lead to the life-threatening complications of vEDS, even at normal
diameter and younger age.
For vEDS, no targeted therapy is available and there is no consensus
on clinical management.3,4 Current management includes antihyperten-
sive drugs as well as medical and surgical treatment of symptoms and
complications. In 2010, a clinical trial showed that the cardioselective
b-blocker celiprolol with b2-agonist vasodilatory properties5,6 reduces
the risk of arterial dissection and rupture, regardless of the underlying
COL3A1 mutation.7 However, it remains unclear whether celiprolol
exerts its beneficial effect by the b-blocker-typical prevention of exces-
sive and short-term rises in blood pressure and heart rate or by improv-
ing the biomechanical integrity of the aortic wall. Another potential
therapeutic approach involves the broad-spectrum antibiotic and matrix
metalloproteinase (MMP) inhibitor doxycycline. In a mouse vEDS model
(Col3a1tm1Jae), doxycycline has been proven to normalize aortic tissue
MMP activity, thereby attenuating the degradation of collagen and ame-
liorating the susceptibility to stress-induced aortic lesions.8,9
In contrast, the medical treatment of aortic aneurysms in Marfan syn-
drome (MFS; OMIM #154700), a connective tissue disorder often in dif-
ferential diagnosis with vEDS, has been extensively studied in mice and
humans. Losartan, an angiotensin II receptor type 1 (AGTR1) antagonist
and indirect inhibitor of transforming growth factor beta (TGFb)-signal-
ling, prevented aortic aneurysm formation in a mouse model of MFS10
and reduced the rate of aortic root dilation in paediatric11 and adult MFS
cases.12 Controversially, a meta-analysis of six randomized, but pharma-
cogenetically non-stratified, trials revealed no clinical outcome benefits
in MFS patients treated with losartan.13 Nevertheless, losartan is often
used to protect MFS patients from unexpected and/or emergency aortic
complications.14 Even though phenotypic overlap between MFS and
vEDS exists, the success of medical therapies can profoundly differ and
the therapeutic role of losartan in vEDS remains elusive.
The first described mouse vEDS model (Col3a1tm1Jae) harbours a null
mutation. Homozygous mice are embryonic lethal, whereas heterozy-
gous mice do not show any obvious phenotype and have no increased
mortality.15 More than a decade after initial description, thorough histo-
logical examination of the aorta of heterozygous mice revealed the pres-
ence of a spectrum of lesions in the aortic walls similar to those observed
in human patients.16 The second mouse vEDS model (Col3a1m1Lsmi) was
generated spontaneously during unrelated experiments and was de-
scribed as truly haploinsufficient for Col3a1 due to a deletion comprising
exon 1. Similar to the first described mouse vEDS model, homozygous
mice are embryonic lethal. However, 28% of heterozygous mice die
due to aortic dissection and/or rupture reflecting the key characteristic of
vEDS and thus we used this model for our study.17 Recently, an additional
mouse model (Col3a1Tg-G182S) was reported, overexpressing a mutant
transcript with a glycine substitution and showing reduced longitudinal
tensile strength of the thoraco-abdominal aorta as well as severe skin
lesions in males18 (Supplementary material online, Table S1).
No previous studies have attempted to confirm or assess the thera-
peutic effect of celiprolol or losartan in vEDS. Here, we use a novel
read-out system with doxycycline as a proof-of-concept drug to assess
whether or not treatment with celiprolol or losartan strengthens the
weakened aortic wall in the Col3a1m1Lsmi mouse vEDS model and thus
could be the therapy of choice in vEDS.
2. Methods
2.1 Animals and treatment
All animal experiments were approved by the local animal ethics com-
mittee (Kantonales Veterinaeramt Zurich, approval reference numbers:
ZH051/12 and ZH096/15) and performed according to local guidelines
(Swiss Animal Protection Ordinance, TschV, and Swiss Animal
Protection Law, TschG), conforming to the guidelines from Directive
2010/63/EU of the European Parliament on the protection of animals
used for scientific purposes.
The vEDS mouse model Col3a1m1Lsmi obtained from MRC Harwell
Laboratories (Oxfordshire, UK)17 was bred in-house, genotyped by PCR
with DNA isolated from ear biopsies, and further characterized using
whole-genome sequencing, long-range PCR followed by long-read se-
quencing using MinION (Oxford Nanopore, Oxford Science Park, UK),
and subsequent transcript analysis as described in the Supplementary
material online. Due to a mixed genetic background (C57BL/6J and
129P/OlaHsd), mice were backcrossed to the C57BL/6J strain (Charles
River Laboratories, Wilmington, MA, USA) prior to the rupture force
measurements. Hereafter, wild-type mice are referred to as Col3a1þ/þ
and heterozygous mice as Col3a1m1Lsmi/þ.
According to previous animal studies, 4-week-old Col3a1m1Lsmi/þ mice
underwent treatment with doxycycline (n= 16, 100 mg/kg/day),8
celiprolol (n= 10; 200 mg/kg/day),19 or losartan (n= 10; 180 mg/kg/
day).10 Mice were weighed at the beginning and end of each treatment.
Littermates were used for untreated control groups of Col3a1þ/þ and
Col3a1m1Lsmi/þ mice, receiving normal drinking water or the correspond-
ing control diet. All treatments were conducted for 4 weeks and in the
case of losartan (n= 10; 180 mg/kg/day) for 8 weeks as well (i.e. from
ages 4 to 12 weeks). Prior to the measurements, genotype and treat-
ment were blinded to the investigator. Treatment details are available in
the Supplementary material online.
2.2 Microscopy
Samples from the thoracic aorta and skin were prepared as reported20
and examined under a FEI CM100 transmission electron microscope
(FEI, Eindhoven, The Netherlands). Using multiphoton microscopy, the
collagen microstructure of aortic tissue under stretching was investi-
gated with a dedicated in situ experimental setup.21,22 3D stacks were
taken at an unstretched configuration and at three stretching steps (from
0 to 1.9, 2.6, and 3.2 mm). Microstructural parameters were quantified
from microscopy images containing only a second harmonic generation
signal using custom scripts in Matlab (The MathWorks Inc., Natick, MA,
USA). Details are available in the Supplementary material online.
2.3 Rupture-force measurement
Immediately following sacrifice using CO2, the thoracic aorta was iso-
lated, excised, and carefully cleaned of adherent connective tissue and fat
in 3-(N-morpholino)-propanesulfonic acid (MOPS) buffer. Subsequently,
1.5-mm-long aortic ring sections (S1–S3) were cut from the ascending
(S1) and descending aorta (S2 and S3) by a custom-made device
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(Supplementary material online, Figure S1A) and mounted on two
200-lm-diameter stainless steel wires placed in MOPS buffer tempered
to 37C to mimic physiological conditions. The mounted aortic rings
were stretched at a constant speed of 5mm/s until tissue rupture using a
uniaxial tension device (Tissue Puller 560TP, Danish Myo Technology,
Aarhus, Denmark), thereby recording the maximum stretching/tensile
force in mN (Supplementary material online, Figure S1B, C). Details on
the custom-made cutting and the uniaxial tension device as well as the
calculations of relative forces used for the comparison of data from dif-
ferent experiments are available in the Supplementary material online.
2.4 Statistical analysis
For arithmetic means, lower and upper confidence limits [95% confi-
dence intervals (CIs)] were calculated using critical values of paired t-test
distribution (vassarstats.net/conf_mean.html). The appropriate test to
calculate numeric P-values for statistical significance between groups was
determined as described in the Supplementary material online, Figure S2.
Using GraphPad Prism 8 (GraphPad Software, La Jolla, CA, USA) differ-
ences between two groups were assessed by two-sample t-test (normal
distribution, equal sample variance), Welch’s t-test (normal distribution,
unequal sample variance), or Mann–Whitney U test (non-normal distri-
bution), while P-values for statistical significance among three groups
were calculated by one-way ANOVA (normal distribution) with Tukey’s
correction or non-parametric Kruskal–Wallis test (non-normal distribu-
tion) with Dunn’s correction. Statistical tests were performed for
planned comparisons only and exact numeric P-values were reported
for P>_ 0.0001 and P<_ 0.9999.
3. Results
3.1 Mouse model characterization
Whole-genome sequencing and subsequent transcript analysis revealed
that the deletion in Col3a1m1Lsmi/þ mice (Chr1:g.45 338 538_45 340
967delins2061) does not lead to a Col3a1 null allele (true haploinsuffi-
ciency) as initially reported,17 but to a shortened transcript with an in-
frame deletion of exons 33-39 [NM_009930.2:c.2281_2820del,
NP_034060.2:p.(Pro762_Gly941del)] potentially affecting normal
collagen processing and/or assembly (Supplementary material online,
Figure S3). Indeed, imaging showed the effect of this in-frame deletion
on protein level. Transmission electron microscopy (TEM) revealed a
Figure 1 Transmission electron microscopy images. (A and B) Cross sections of collagen fibrils in the adventitia of the thoracic aorta from (A) Col3a1þ/þ
(WT) and (B) Col3a1m1Lsmi/þ (Het) mice. Black arrows point to individual fibrils. (C and D) Skin sections of (C) WT and (D) Het mice are shown. Blue arrow
indicates longitudinal aligned bundles of collagen fibrils, which are only displayed in the tissue from WT animals. Magnification: 24 500. For collagen fibril di-
ameter distribution, see Supplementary material online, Figure S4.
Celiprolol but not losartan increases the aortic rupture force in mice modelling vEDS 459
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reduced number as well as more variable and oversized diameters of
collagen fibrils in the adventitia of the thoracic aorta and in the skin
of Col3a1m1Lsmi/þ mice compared to Col3a1þ/þ animals (Figure 1;
Supplementary material online, Figure S4). Accordingly, multiphoton mi-
croscopy (MPM) images of aortic wall samples revealed considerably
less collagen amount [981 570 (95% CI 889 968–1 073 173) mm3 vs.
1 443 702 (95% CI 966 868–1 920 535) mm3] and density [0.070 (95% CI
0.052–0.087) vs. 0.132 (95% CI 0.061–0.203)] in a relaxed configuration
as well as delayed and reduced reorienting and aligning upon stretching
in Col3a1m1Lsmi/þ mice in comparison to Col3a1þ/þ mice (Figure 2;
Supplementary material online, Table S2).
In order to assess whether or not there is a measurable difference in
the biomechanical integrity of the thoracic aorta between Col3a1m1Lsmi/þ
and Col3a1þ/þ mice, the maximum tensile force of 1.5-mm-long aortic
rings was measured for three aortic sections (S1–S3) (Figure 3A). In
Col3a1þ/þ mice, the maximum tensile force decreases with increasing
distance from the heart regardless of age (Figure 3B; Supplementary ma-
terial online, Table S3). This tendency was also present in aortic sections
of Col3a1m1Lsmi/þ mice, although less pronounced (Figure 3C;
Supplementary material online, Table S3). More importantly, maximum
tensile forces of aortic rings from Col3a1m1Lsmi/þ mice were significantly
lower compared to Col3a1þ/þ mice in all three aortic sections at
ages from 6 weeks [e.g. S1 in 6- to 7-week-old males: 347.0 (95% CI
279.3–414.7) mN vs. 638.2 (95% CI 573.2–703.2) mN] (Figure 3C;
Supplementary material online, Table S3). No considerable differences in
rupture forces were measured between male and female mice
(Supplementary material online, Figure S5 and Table S3).
3.2 Doxycycline, celiprolol, and losartan
treatments
Premature deaths of Col3a1m1Lsmi/þ mice due to aortic ruptures were
observed during the early phase of treatments (doxycycline: 7/16; losar-
tan 4 weeks and 8 weeks: each 1/10; celiprolol: 0/10) and are in relation
to the respective untreated heterozygous control groups (doxycycline:
4/16; losartan and celiprolol 4 weeks: 0/10; losartan 8 weeks: 2/10)
(Supplementary material online, Tables S4 and S5). Measurements in the
remaining mice revealed that treatment with doxycycline increased the
maximum tensile force of the thoracic aortic wall in Col3a1m1Lsmi/þ mice
[S1 470.3 (95% CI 443.0–497.5) mN, S2 404.8 (95% CI 381.7–427.8)
mN, S3 281.9 (95% CI 248.6–315.2) mN] to levels comparable to
Col3a1þ/þ mice [S1 523.1 (95% CI 498.4–547.9) mN, S2 405.9 (95% CI
Figure 2 Collagen distribution in the aortic wall imaged by multiphoton microscopy. (A–C) Second harmonic generation signal emitted by collagen in
the aortic wall of 11-week-old mice is shown in green. (A and B) 3D images of a cross-section of the aortic wall at unstretched configuration of (A)
Col3a1þ/þ (WT) and (B) Col3a1m1Lsmi/þ (Het) mice. (C) 2D images made at relaxed configuration and displacements (k) of 1.9, 2.6, and 3.2 mm. Red
arrows indicate stretched collagen structures in the tissue from a WT mouse.
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..371.2–440.7) mN, S3 333.7 (95% CI 305.8–361.6) mN] (Figure 4A;
Supplementary material online, Table S6). This is in line with previous
findings in a different mouse model of vEDS [Col3a1tm1Jaemice]8,9 and
thus acts as a proof-of-concept for our novel approach and read-out sys-
tem. Similarly, 4-week treatment with the b-blocker celiprolol [S2 395.2
(95% CI 363.5–426.9) mN, S3 303.3 (95% CI 281.6–325.1) mN] led to a
significantly higher rupture force in the descending aorta (S2 and S3)
when compared to untreated Col3a1m1Lsmi/þ mice [S2 296.7 (95% CI
261.9–331.5) mN, S3 245.5 (95% CI 220.7–270.3) mN]. A similar trend,
although not significant, was observed for the segment derived from the
ascending aorta [S1 483.9 (95% CI 448.8–519.0) mN vs. 400.3 (95% CI
347.3–453.3) mN] (Figure 4B; Supplementary material online, Table S6).
In contrast, no significant increase was detected in the rupture force
upon 4-week losartan treatment [S1 358.5 (95% CI 332.7–384.3) mN,
S2 290.9 (95% CI 246.4–335.4) mN, S3 239.4 (95% CI 200.0–278.8)
mN] (Figure 4C; Supplementary material online, Table S6). Comparison
among the normalized data of treated mice showed that celiprolol treat-
ment was not significantly different from doxycycline treatment, while
both treatments resulted in significantly higher rupture forces than the
treatment with losartan (Figure 4D). To assess whether losartan requires
a longer time span to elicit its actual potential, Col3a1m1Lsmi/þ mice
underwent an 8-week losartan treatment as well. However, even after
8 weeks, losartan did not significantly increase the rupture force of the
thoracic aorta (Supplementary material online, Figure S6 and Table S7).
4. Discussion
Using a novel read-out system, we confirmed the beneficial effect of
doxycycline in mice modelling vEDS and showed that celiprolol consid-
erably increases the biomechanical integrity of the thoracic aorta,
whereas we did not observe any improvement upon losartan treatment
(Figures 4 and 5). To date, studies testing novel medical therapeutic
approaches for aortic diseases have mostly been based on morbidity
(e.g. aneurysm progression, dissection), mortality, or histological analyses
to assess treatment efficacy. However, while these methods provide
qualitative insights, they cannot objectively reveal how the treatment
influences the strength (i.e. biomechanical integrity) of the aortic wall
which ultimately determines whether or not a drug is effective to pre-
vent aortic dissection and rupture. Thus, we developed a novel approach
Figure 3 Tensile force at rupture of the murine thoracic aorta. (A) Location of the three 1.5-mm-long ring sections in the ascending (section S1) and
descending (sections S2 and S3) aorta. Aorta and heart from a Col3a1þ/þ mouse were stained with yellow latex as described in the Supplementary mate-
rial online. (B) Maximum tensile forces (mN) of the three aortic sections from Col3a1þ/þ mice and (C) comparison between Col3a1þ/þ (WT) and
Col3a1m1Lsmi/þ (Het) male mice at ages of 4–5, 6–7, and 9–11 weeks. For comparison to data of females see Supplementary material online, Figure S5.
Sample size (n) is displayed and individual values are listed in Supplementary material online, Table S3. Data are means with error bars indicating 95% CIs.
Significant differences (P< 0.05) are shown in blue. One-way ANOVA analysis with Tukey’s correction (B) and unpaired two-sample t-test or Welch’s t-
test was performed where appropriate (C). †denotes statistically significant difference between groups (means) of measurements with overlapping CIs.
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..to measure the tensile force at rupture of uniaxially stretched murine
aortic rings as an objective read-out of the biomechanical integrity of the
aortic wall.
A first indication of the validity of our novel read-out system is the, de-
spite potential variability in the aortic segment length of 1.5 mm, signifi-
cantly lower maximum tensile force measured in Col3a1m1Lsmi/þ
compared to Col3a1þ/þ mice, reflecting the increased mortality due to
aortic rupture.17 Second, these results were reproduced in three differ-
ent measured sections (S1–S3) (Figure 3A). Third, we provided proof of
concept for the suitability of the used maximum tensile force measure-
ments and Col3a1m1Lsmi/þ mouse model by confirming the positive effect
of MMP inhibition by doxycycline reported for the true-haploinsufficient
vEDS mouse model Col3a1tm1Jae.8,9 Consequently, our read-out system
is suitable to test candidate substances for their potential to reduce the
risk for aortic ruptures.
Significant differences between Col3a1þ/þ and Col3a1m1Lsmi/þ mice
from an early age are likely explained by differences in intramural colla-
gen content. At a molecular level, we showed that the spontaneously de-
rived mutation in Col3a1m1Lsmi/þ mice results in a shortened transcript
(in-frame deletion) but not in true haploinsufficiency as initially
suggested.17 This finding may explain the more severe aortic phenotype
compared to the true haploinsufficiency model Col3a1tm1Jae
(Supplementary material online, Table S1). In Col3a1m1Lsmi/þ mice,
TEM and MPM revealed a reduction in total collagen content, higher vari-
ability in collagen fibril diameter, and delayed alignment of collagen struc-
tures upon tensile stress. These data suggest reduced type III collagen
secretion as shown in vEDS patients with in-frame transcript dele-
tions.23,24 As most vEDS-causing mutations, including the most fre-
quently identified glycine substitutions, lead to the impaired secretion of
type III collagen and a reduced total collagen content,18 our results
obtained with the Col3a1m1Lsmi/þ mice are expected to be transferable
to most cases of vEDS. Moreover, the mutation-independent effect of
celiprolol is supported by the clinical study in 2010, in which the risk of
arterial dissection and rupture was reduced regardless of the underlying
COL3A1 mutation.7 Since neither the applied TEM nor MPM techniques
allow discrimination between different types of collagens, however, it
remains to be determined whether the observed differences in
rupture force and collagen characteristics solely reflect a reduced
amount of normal type III collagen or whether other types of collagens
are affected as well. Indeed, copolymers between type I and type III colla-
gens can form25,26 and disturbed fibrillogenesis of heterotypic type III:I
collagen fibril assembly has recently been reported in mice overexpress-
ing Col3a1 harbouring a glycine substitution (Supplementary material
online, Table S1).18
Figure 4 Treatment with doxycycline or celiprolol but not losartan increases the biomechanical integrity in Col3a1m1Lsmi/þ mice. (A–C) Col3a1m1Lsmi/þ
(Het) mice underwent a 4-week treatment with (A) doxycycline, (B) celiprolol, or (C) losartan. Maximum tensile force (mN) was measured for three tho-
racic aortic sections (S1–S3) (Figure 3A) and compared to untreated Col3a1þ/þ (WT) and Het controls. (D) Normalized comparison of the effects of the
different treatments on maximum tensile force (significant differences to untreated controls are not marked). Note that the same control groups were
used for the celiprolol and losartan treatments. Sample size (n) is displayed. Aortas of mice that died prematurely or that were damaged during prepara-
tion were excluded (Supplementary material online, Table S4). Data are means with error bars indicating 95% CIs. Significant differences (P< 0.05) are
shown in blue. One-way ANOVA analysis with Tukey’s correction or Kruskal–Wallis test with Dunn’s correction was performed where appropriate.
†denotes statistically significant difference between groups (means) of measurements with overlapping CIs.
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.Our results demonstrate that doxycycline significantly improves
the biomechanical integrity of the thoracic aorta in Col3a1m1Lsmi/þ mice
(Figure 4A). This finding confirms and extends previous histological evidence
that doxycycline ameliorates aortic lesions in the true-haploinsufficient
vEDS mouse model Col3a1tm1Jae by MMP inhibition.8,9 However, consider-
ing that doxycycline is a broad-spectrum antibiotic and has considerable
side effects including severe photosensitivity27 it becomes an unattractive
choice for life-long therapy. In contrast, antihypertensive drugs such as the
b-blocker celiprolol or the AGTR1-antagonist losartan have milder side
effects and thus are more suitable for a long-term therapy. For example, cel-
iprolol, which was designated orphan drug status by the FDA in 2015 for
the treatment of vEDS,28 may lead to fatigue and an upset stomach,29
whereas the most common side effects of losartan are dizziness, acute na-
sopharyngeal infections, and musculoskeletal pain.30
This is the first study demonstrating that celiprolol improves the biome-
chanical integrity of the thoracic aorta in an experimental model of vEDS
(Figure 4B). In humans, celiprolol was previously shown to reduce heart
rate as well as mean and pulsatile pressures in essential hypertension by
blocking b1-adrenoceptors, thereby moderating the positive chronotropic
effects of sympathetic arousal and highly likely decreasing the continuous
and pulsatile mechanical stress on collagen fibres within the arterial
wall.31,32 The clinical trial with celiprolol, however, revealed no reduction
in brachial systolic and diastolic blood pressure but an increased stiffness of
the common carotid artery, regardless of the underlying COL3A1 muta-
tion.7 In consideration of the findings of our study, the increased arterial
stiffness after long-term treatment of vEDS patients with celiprolol7 might
reflect an improved biomechanical integrity of the aortic wall. Indeed, be-
sides the b-blocker typical action, celiprolol stimulates NO production and
thus may reduce vascular oxidative stress,19,33,34 which could beneficially
impact the extracellular matrix, ensuring a more intact aortic wall.
However, the understanding of the underlying effect of celiprolol causing a
strengthening of the aortic wall remains to be elucidated.
Considering that losartan has previously been shown to reduce aortic
aneurysm progression in mice modelling MFS,10 another clinically highly
relevant finding of our study is that losartan does not improve the bio-
mechanical integrity of the thoracic aorta neither after 4 nor after
8 weeks of treatment in a mouse vEDS model (Figure 4C; Supplementary
material online, Figure S6). Although it is believed that the blockade of
AGTR1 and thus indirect inhibition of TGFb-signalling confers the posi-
tive effect of preventing aortic root dilation in MFS, recent studies are
challenging the pathogenic driver role of TGFb and its signalling35,36 as
well as the mode of action of losartan.37 Nevertheless, evidence that los-
artan does not improve the biomechanical integrity of the aorta is essen-
tial, even derived from an experimental model, as losartan is not only
widely used for disease management of MFS but is also considered for
related aortic diseases including vEDS.
We administered losartan and celiprolol in dosages comparable to
previous animal studies.10,19 For the clinical translation, the human equiv-
alent dose can be estimated by applying a species conversion factor of
0.081 based on body surface and weight.38 The resulting human
Figure 5 Schematic representation of the workflow in this study. (1) The mouse vEDS model Col3a1m1Lsmi was characterized at DNA, mRNA, and pro-
tein levels. (2) A novel read-out using the Tissue Puller 560TP (DMT) to measure the aortic rupture force was developed and subsequently validated us-
ing doxycycline as a proof-of-concept drug. (3) Mice modelling vEDS were treated with celiprolol or losartan. (4) The aortic rupture force was measured
to compare the treatment efficacy, showing that celiprolol but not losartan increases the rupture force of the aorta in this experimental vEDS model.
MPM, multiphoton microscopy; TEM, transmission electron microscopy; vEDS, vascular Ehlers–Danlos syndrome; WGS, whole-genome sequencing.
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.
equivalent dosages for a 75-kg patient (1200 mg celiprolol or
1100 mg losartan per day) are substantially higher than the routinely
administered safety approved doses (up to 400 mg celiprolol or 150 mg
losartan per day). The approved lower dosage of celiprolol (100–400 mg
per day), which has been shown to be efficient in vEDS after long-term
treatment,7 is likely sufficient and more adequate for vEDS patients.
Moreover, human dosages may need to be further adjusted according
to individual pharmacogenetic predisposition. For instance, losartan
requires CYP2C9-mediated activation into its more potent metabolite
E-3174,39 of which20–30% of Caucasians are possible poor metaboliz-
ers40 and thus may require higher dosages. The mouse genome contains
2 homologues and 10 orthologues of the CYP2C9 gene,41 likely leading
to increased losartan activation and thus hampering the mouse-to-
human dosage translation. In contrast, celiprolol is only metabolized to a
minor extent,31,42 representing an additional advantage over losartan. To
enable optimal treatment through precision medicine, further appropri-
ately stratified studies and thoughtful dosage regimens are required.
There are some limitations to our study: (i) the maximum tensile
forces determined ex vivo by our read-out system might not entirely re-
flect rupture forces in physiological in vivo conditions with long-term pul-
satile pressure in arteries, which could lead to rupture at lower loads.
Moreover, in our set up, using aortic rings, we apply only circumferential
stress but not axial stress, the influence of which is difficult to predict but
expected to be low or neglectable since according to the Laplace law,
the circumferential component of the stress generated by blood pres-
sure is higher than the axial component. (ii) The role of blood pressure
on the mortality as well as the influence on treatment efficacy remains
open and needs to be assessed in future studies.
Taken together, we demonstrated in a mouse vEDS model that celi-
prolol rather than losartan beneficially impacts the biomechanical integ-
rity of the thoracic aorta, providing evidence for celiprolol as medical
therapy of choice in vEDS. This result supports previous data suggesting
that the delay or prevention of arterial events is not solely achieved by
celiprolol’s blood pressure modulating capacity but also by a direct im-
pact on the arterial wall.7 Moreover, a blood pressure-independent
mode of action is supported by the finding that losartan, another tested
antihypertensive drug, did not improve the biomechanical integrity of
the aorta in the same vEDS model. However, losartan, effective in MFS
patients, is increasingly considered or even prescribed for the non-
evidence-based treatment of patients with MFS-related aortic condi-
tions. Thus, there is a need to rethink the current paradigm that a medi-
cal therapy may be of benefit in phenotypically similar diseases but rather
to consider the disease-underlying molecular mechanisms.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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Translational perspective
Aortic dissection and rupture belong to the major complications of vascular Ehlers–Danlos syndrome (vEDS). Medical
management includes antihypertensive drugs but there are no comparative data for drug selection. This study shows that the
b-blocker celiprolol significantly improves the biomechanical integrity of the thoracic aorta in an experimental model of vEDS,
explaining the treatment effect in a clinical trial. In contrast, the AGTR1-antagonist losartan, widely used to prevent or stabilize
aortic dilation in the phenotypically overlapping Marfan syndrome, did not have a beneficial effect. These findings provide
further evidence that celiprolol rather than losartan may be the medical therapy of choice in vEDS.
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